Share This Article:

Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose

Abstract Full-Text HTML XML Download Download as PDF (Size:545KB) PP. 943-953
DOI: 10.4236/jct.2015.611102    2,807 Downloads   3,266 Views  

ABSTRACT

Purpose: To investigate the toxicity, survival and patterns of failure in patients with advanced lung cancer treated with intensity modulated radiation therapy (IMRT) and chemotherapy. Methods and Materials: Retrospective chart review of 68 total patients: 46 academic and 22 community center. Endpoints: Grade ≥ 3 pneumonitis, Grade ≥ 2 esophagitis, local, regional and distant failure, progression-free survival (PFS) and overall survival (OS). Results: For the academic center patients, median follow-up was 19.2 months. Esophagitis: 0% Grade 3, 35% Grade 2, no significant difference between dose bins: <70 Gy vs. 70 Gy, 25% vs. 45% (p = 0.22), <66 Gy vs. 66 - 70 Gy, 28% vs. 39% (p = 0.53). Lung dose metrics and PTV size were not associated with Grade ≥ 3 pneumonitis. Esophageal V35, V50, and mean dose but not PTV size was associated with Grade 2 esophagitis. 1 year local, regional and distant failure = 6.5%, 6.5%, and 30.4%. No endpoint differences were seen between dose bins, though patients with smaller PTVs treated with 70 Gy did demonstrate improved OS (ns) when compared to those treated with <70 Gy. Community Center: Median follow-up 6.2 months with 15% Grade 2 esophagitis, no Grade 3 esophagitis. Two patients (9%) experienced Grade ≥ 3 pneumonitis. Conclusions: IMRT chemoradiation was well tolerated in a population with advanced NSCLC both in the academic and community settings. Severe pneumonitis rates were low and comparable to other series using IMRT and chemotherapy. Esophagitis was mild and associated with V35, V50 and mean dose. No significant benefit was seen for higher doses regarding survival, local, regional or distant control despite that higher dose bins had smaller tumors. Though not statistically significant, we did find a trend toward worse OS for <70 Gy when the PTV was less than the median PTV.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Russo, J. , Grass, D. , Armeson, K. , Stahl, J. , Dufan, T. , Reynolds, J. , Luebke, A. and Sharma, A. (2015) Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose. Journal of Cancer Therapy, 6, 943-953. doi: 10.4236/jct.2015.611102.

References

[1] Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer Statistics. CA: A Cancer Journal for Clinicians, 63, 11-30.
http://dx.doi.org/10.3322/caac.21166
[2] Ramnath, N., Dilling, T.J., Harris, L.J., et al. (2013) Treatment of Stage III Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, e314S-e340S.
[3] Rengan, R., Rosenzweig, K.E., Venkatraman, E., et al. (2004) Improved Local Control with Higher Doses of Radiation in Large-Volume Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 60, 741-747.
http://dx.doi.org/10.1016/j.ijrobp.2004.04.013
[4] Grills, I.S., Yan, D., Martinez, A.A., et al. (2003) Potential for Reduced Toxicity and dose Escalation in the Treatment of Inoperable Non-Small-Cell Lung Cancer: A Comparison of Intensity-Modulated Radiation Therapy (IMRT), 3D Conformal Radiation, and Elective Nodal Irradiation. International Journal of Radiation Oncology, Biology, Physics, 57, 875-890.
http://dx.doi.org/10.1016/S0360-3016(03)00743-0
[5] Gaspar, L.E. and Ding, M. (2008) A Review of Intensity-Modulated Radiation Therapy. Current Oncology Reports, 10, 294-299.
http://dx.doi.org/10.1007/s11912-008-0046-3
[6] Yom, S.S., Liao, Z., Liu, H.H., et al. (2007) Initial Evaluation of Treatment-Related Pneumonitis in Advanced-Stage Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 68, 94-102.
http://dx.doi.org/10.1016/j.ijrobp.2006.12.031
[7] Sura, S., Gupta, V., Yorke, E., et al. (2008) Intensity-Modulated Radiation Therapy (IMRT) for Inoperable Non-Small Cell Lung Cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) Experience. Radiotherapy and Oncology, 87, 17-23.
http://dx.doi.org/10.1016/j.radonc.2008.02.005
[8] Fletcher, G.H. (1973) Clinical Dose-Response Curves of Human Malignant Epithelial Tumours. British Journal of Radiology, 46, 1-12.
http://dx.doi.org/10.1259/0007-1285-46-541-1
[9] Chang, A.J. and Bradley, J.D. (2010) Clinical Perspectives on Dose Escalation for Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 11, 299-302.
http://dx.doi.org/10.3816/CLC.2010.n.037
[10] Bradley, J., Paulus, R., Komaki, R., et al. (2015) Standard-Dose versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB Non-Small-Cell Lung Cancer (RTOG 0617): A Randomised, Two-by-Two Factorial Phase 3 Study. The Lancet Oncology, 16, 187-199.
http://dx.doi.org/10.1016/S1470-2045(14)71207-0
[11] Machtay, M., Bae, K., Movsas, B., Paulus, R., Gore, E.M., Komaki, R., et al. (2012) Higher Biologically Effective Dose of Radiotherapy Is Associated with Improved Outcomes for Locally Advanced Non-Small Cell Lung Carcinoma Treated with Chemoradiation: An Analysis of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology, Biology, Physics, 82, 425-434.
http://dx.doi.org/10.1016/j.ijrobp.2010.09.004
[12] Kong, F.-M., Haken, R.K.T., Schipper, M.J., Sullivan, M.A., Chen, M., Lopez, C., et al. (2005) High-Dose Radiation Improved Local Tumor Control and Overall Survival in Patients with Inoperable/Unresectable Non-Small-Cell Lung Cancer: Long-Term Results of a Radiation Dose Escalation Study. International Journal of Radiation Oncology, Biology, Physics, 63, 324-333.
http://dx.doi.org/10.1016/j.ijrobp.2005.02.010
[13] Zhang, P., Hugo, G.D. and Yan, D. (2008) Planning Study Comparison of Real-Time Target Tracking and Four-Dimensional Inverse Planning for Managing Patient Respiratory Motion. International Journal of Radiation Oncology, Biology, Physics, 72, 1221-1227.
http://dx.doi.org/10.1016/j.ijrobp.2008.07.025
[14] Guckenberger, M., Wilbert, J., Richter, A., Baier, K. and Flentje, M. (2011) Potential of Adaptive Radiotherapy to Escalate the Radiation Dose in Combined Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 79, 901-908.
http://dx.doi.org/10.1016/j.ijrobp.2010.04.050
[15] Liao, Z.X., Komaki, R., Thames, H.D., Liu, H.H., Tucker, S.L., Mohan, R., et al. (2010) Influence of Technologic Advances on Outcomes in Patients with Unresectable, Locally Advanced Non-Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics, 76, 775-781.
http://dx.doi.org/10.1016/j.ijrobp.2009.02.032
[16] Guckenberger, M., Kavanagh, A. and Partridge, M. (2012) Combining Advanced Radiotherapy Technologies to Maximize Safety and Tumor Control Probability in Stage III Non-Small Cell Lung Cancer. Strahlentherapie und Onkologie, 188, 894-900.
http://dx.doi.org/10.1007/s00066-012-0161-9
[17] Shirvani, S.M., Jiang, J., Gomez, D.R., Chang, J.Y., Buchholz, T.A. and Smith, B.D. (2013) Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in the United States: Predictors of Use and Association with Toxicities. Lung Cancer, 82, 252-259.
http://dx.doi.org/10.1016/j.lungcan.2013.08.015
[18] Wang, S.L., Liao, Z.X., Wei, X., Liu, H.H., Tucker, S.L., Hu, C.-S., et al. (2006) Analysis of Clinical and Dosimetric Factors Associated with Treatment-Related Pneumonitis (TRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy and Three-Dimensional Conformal Radiotherapy (3D-CRT). International Journal of Radiation Oncology, Biology, Physics, 66, 1399-1407.
http://dx.doi.org/10.1016/j.ijrobp.2006.07.1337
[19] Hall, E.J. (2006) Intensity-Modulated Radiation Therapy, Protons, and the Risk of Second Cancers. International Journal of Radiation Oncology, Biology, Physics, 65, 1-7.
http://dx.doi.org/10.1016/j.ijrobp.2006.01.027
[20] Murshed, H., Liu, H.H., Liao, Z.X., Barker, J.L., Wang, X.C., Tucker, S.L., et al. (2004) Dose and Volume Reduction for Normal Lung Using Intensity-Modulated Radiotherapy for Advanced-Stage Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 58, 1258-1267.
http://dx.doi.org/10.1016/j.ijrobp.2003.09.086
[21] Liu, H.H., Wang, X.C., Dong, L., Wu, Q.W., Liao, Z.X., Stevens, C.W., et al. (2004) Feasibility of Sparing Lung and Other Thoracic Structures with Intensity-Modulated Radiotherapy for Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 58, 1268-1279.
http://dx.doi.org/10.1016/j.ijrobp.2003.09.085
[22] Jiang, Z.-Q., Yang, K.Y., Komaki, R., Wei, X., Tucker, S.L., Zhuang, Y., et al. (2012) Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience. International Journal of Radiation Oncology, Biology, Physics, 83, 332-339.
http://dx.doi.org/10.1016/j.ijrobp.2011.06.1963
[23] Shi, A.H., Zhu, G.Y., Wu, H., Yu, R., Li, F.H. and Xu, B. (2010) Analysis of Clinical and Dosimetric Factors Associated with Severe Acute Radiation Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. Radiation Oncology, 5, 35.
http://dx.doi.org/10.1186/1748-717x-5-35
[24] Govaert, S.L.A., Troost, E.G.C., Schuurbiers, O.C.J., de Geus-Oei, L.-F., Termeer, A., Span, P.N. and Bussink, J. (2012) Treatment Outcome and Toxicity of Intensity-Modulated (Chemo) Radiotherapy in Stage III Non-Small Cell Lung Cancer Patients. Radiation Oncology, 7, 150.
http://dx.doi.org/10.1186/1748-717x-7-150
[25] Marks, L.B., Bentzen, S.M., Deasy, J.O., Kong, F.-M., Bradley, J.D., Vogelius, I.S., et al. (2010) Radiation Dose-Volume Effects in the Lung. International Journal of Radiation Oncology, Biology, Physics, 76, S70-S76.
http://dx.doi.org/10.1016/j.ijrobp.2009.06.091
[26] Werner-Wasik, M., Yorke, E., Deasy, J.O., Nam, J. and Marks, L.B. (2010) Radiation Dose-Volume Effects in the Esophagus. International Journal of Radiation Oncology, Biology, Physics, 76, S86-S93.
http://dx.doi.org/10.1016/j.ijrobp.2009.05.070
[27] Bradley, J.D., Deasy, J.O., Bentzen, S.M. and El Naqa, I. (2004) Dosimetric Correlates for Acute Esophagitis in Patients Treated with Radiotherapy for Lung Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 58, 1106-1113.
http://dx.doi.org/10.1016/j.ijrobp.2003.09.080
[28] Maguire, P.D., Sibley, G.S., Zhou, S.-M., Jamieson, T.A., Light, K.L. and Antoine, P.A. (1999) Clinical and Dosimetric Predictors of Radiation-Induced Esophageal Toxicity. International Journal of Radiation Oncology, Biology, Physics, 45, 97-103.
http://dx.doi.org/10.1016/S0360-3016(99)00163-7
[29] Singh, A.K., Lockett, M.A. and Bradley, J.D. (2003) Predictors of Radiation-Induced Esophageal Toxicity in Patients with Non-Small-Cell Lung Cancer Treated with Three-Dimensional Conformal Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 55, 337-341.
http://dx.doi.org/10.1016/S0360-3016(02)03937-8
[30] Jensen, A.D., Munter, M.W., Bischoff, H.G., Haselmann, R., Haberkorn, U., Huber, P.E., et al. (2011) Combined Treatment of Nonsmall Cell Lung Cancer NSCLC Stage III with Intensity-Modulated RT Radiotherapy and Cetuximab: The NEAR Trial. Cancer, 117, 2986-2994.
http://dx.doi.org/10.1002/cncr.25888
[31] Uyterlinde, W., Chen, C., Kwint, M., de Bois, J., Vincent, A., Sonke, J.-J., et al. (2013) Prognostic Parameters for Acute Esophagus Toxicity in Intensity Modulated Radiotherapy and Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 107, 392-397.
http://dx.doi.org/10.1016/j.radonc.2013.04.012
[32] Kwint, M., Uyterlinde, W., Nijkamp, J., Chen, C., de Bois, J., Sonke, J.-J., et al. (2012) Acute Esophagus Toxicity in Lung Cancer Patients after Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. International Journal of Radiation Oncology, Biology, Physics, 84, 223-228.
http://dx.doi.org/10.1016/j.ijrobp.2012.03.027
[33] Wurstbauer, K., Deutschmann, H., Dagn, K., Kopp, P., Zehentmayr, F., Lamprecht, B., et al. (2013) DART-Bid (Dose-Differentiated Accelerated Radiation Therapy, 1.8 Gy Twice Daily)—A Novel Approach for Non-Resected NSCLC: Final Results of a Prospective Study, Correlating Radiation Dose to Tumor Volume. Radiation Oncology, 8, 49.
http://dx.doi.org/10.1186/1748-717x-8-49
[34] van Elmpt, W., De Ruysscher, D., van der Salm, A., Lakeman, A., van der Stoep, J., Emans, D., et al. (2012) The PET-Boost Randomised Phase II Dose-Escalation Trial in Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 104, 67-71.
http://dx.doi.org/10.1016/j.radonc.2012.03.005

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.